Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

Jane M. Borkowski, Mary Duerr, Ross C Donehower, Eric K. Rowinsky, Tian Ling Chen, David S Ettinger, Louise B. Grochow

Research output: Contribution to journalArticle

Abstract

Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between age and clearance rate for anticancer drugs in phase I trials at the Johns Hopkins Oncology Center. In a retrospective study, we examined the clinical and pharmacokinetic data for 344 adults (aged 21-77 years) who received 9 phase I drugs with linear clearance in 13 clinical trials. We sought correlations between age and clearance for each drug and for the whole group. Data available for 9 of the 13 trials were used to compare age (65 years) versus dose delivered [<the maximum tolerated dose (MTD) vs ≥ the MTD] or toxicity (<grade 3 vs ≥ grade 3). Of 344 patients, 81 (23.5%) were >65 years old, 34 (9.9%) were ≥70 years old, and 5 (1.5%) were ≥75 years old. There was no significant correlation between drug clearance and age for individual drugs or the group as a whole. There was no significant difference between patients of the older and younger age groups with regard to dose or toxicity. Although only a small number of patients aged ≥75 years were treated, our results suggest that the elderly do not experience greater toxicity even when treated at doses comparable with those given younger patients and should not be excluded from phase I trials on the basis of age. As the population of the United States ages, more elderly patients will be candidates for chemotherapy. A more thorough examination of the relationships between age, clearance rate, and toxicity can be accomplished as active drugs enter phase II/III studies.

Original languageEnglish (US)
Pages (from-to)493-496
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number6
DOIs
StatePublished - Nov 1994

Fingerprint

Investigational Drugs
Pharmacokinetics
Pharmaceutical Preparations
Toxicity
Chemotherapy
Aging of materials
Drug Therapy
Oncology
Retrospective Studies
Age Groups
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. / Borkowski, Jane M.; Duerr, Mary; Donehower, Ross C; Rowinsky, Eric K.; Chen, Tian Ling; Ettinger, David S; Grochow, Louise B.

In: Cancer Chemotherapy and Pharmacology, Vol. 33, No. 6, 11.1994, p. 493-496.

Research output: Contribution to journalArticle

Borkowski, Jane M. ; Duerr, Mary ; Donehower, Ross C ; Rowinsky, Eric K. ; Chen, Tian Ling ; Ettinger, David S ; Grochow, Louise B. / Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 33, No. 6. pp. 493-496.
@article{e10a626f76834d82983f330923b7819f,
title = "Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data",
abstract = "Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between age and clearance rate for anticancer drugs in phase I trials at the Johns Hopkins Oncology Center. In a retrospective study, we examined the clinical and pharmacokinetic data for 344 adults (aged 21-77 years) who received 9 phase I drugs with linear clearance in 13 clinical trials. We sought correlations between age and clearance for each drug and for the whole group. Data available for 9 of the 13 trials were used to compare age (65 years) versus dose delivered [65 years old, 34 (9.9{\%}) were ≥70 years old, and 5 (1.5{\%}) were ≥75 years old. There was no significant correlation between drug clearance and age for individual drugs or the group as a whole. There was no significant difference between patients of the older and younger age groups with regard to dose or toxicity. Although only a small number of patients aged ≥75 years were treated, our results suggest that the elderly do not experience greater toxicity even when treated at doses comparable with those given younger patients and should not be excluded from phase I trials on the basis of age. As the population of the United States ages, more elderly patients will be candidates for chemotherapy. A more thorough examination of the relationships between age, clearance rate, and toxicity can be accomplished as active drugs enter phase II/III studies.",
author = "Borkowski, {Jane M.} and Mary Duerr and Donehower, {Ross C} and Rowinsky, {Eric K.} and Chen, {Tian Ling} and Ettinger, {David S} and Grochow, {Louise B.}",
year = "1994",
month = "11",
doi = "10.1007/BF00686507",
language = "English (US)",
volume = "33",
pages = "493--496",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

AU - Borkowski, Jane M.

AU - Duerr, Mary

AU - Donehower, Ross C

AU - Rowinsky, Eric K.

AU - Chen, Tian Ling

AU - Ettinger, David S

AU - Grochow, Louise B.

PY - 1994/11

Y1 - 1994/11

N2 - Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between age and clearance rate for anticancer drugs in phase I trials at the Johns Hopkins Oncology Center. In a retrospective study, we examined the clinical and pharmacokinetic data for 344 adults (aged 21-77 years) who received 9 phase I drugs with linear clearance in 13 clinical trials. We sought correlations between age and clearance for each drug and for the whole group. Data available for 9 of the 13 trials were used to compare age (65 years) versus dose delivered [65 years old, 34 (9.9%) were ≥70 years old, and 5 (1.5%) were ≥75 years old. There was no significant correlation between drug clearance and age for individual drugs or the group as a whole. There was no significant difference between patients of the older and younger age groups with regard to dose or toxicity. Although only a small number of patients aged ≥75 years were treated, our results suggest that the elderly do not experience greater toxicity even when treated at doses comparable with those given younger patients and should not be excluded from phase I trials on the basis of age. As the population of the United States ages, more elderly patients will be candidates for chemotherapy. A more thorough examination of the relationships between age, clearance rate, and toxicity can be accomplished as active drugs enter phase II/III studies.

AB - Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between age and clearance rate for anticancer drugs in phase I trials at the Johns Hopkins Oncology Center. In a retrospective study, we examined the clinical and pharmacokinetic data for 344 adults (aged 21-77 years) who received 9 phase I drugs with linear clearance in 13 clinical trials. We sought correlations between age and clearance for each drug and for the whole group. Data available for 9 of the 13 trials were used to compare age (65 years) versus dose delivered [65 years old, 34 (9.9%) were ≥70 years old, and 5 (1.5%) were ≥75 years old. There was no significant correlation between drug clearance and age for individual drugs or the group as a whole. There was no significant difference between patients of the older and younger age groups with regard to dose or toxicity. Although only a small number of patients aged ≥75 years were treated, our results suggest that the elderly do not experience greater toxicity even when treated at doses comparable with those given younger patients and should not be excluded from phase I trials on the basis of age. As the population of the United States ages, more elderly patients will be candidates for chemotherapy. A more thorough examination of the relationships between age, clearance rate, and toxicity can be accomplished as active drugs enter phase II/III studies.

UR - http://www.scopus.com/inward/record.url?scp=0028346996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028346996&partnerID=8YFLogxK

U2 - 10.1007/BF00686507

DO - 10.1007/BF00686507

M3 - Article

C2 - 8137460

AN - SCOPUS:0028346996

VL - 33

SP - 493

EP - 496

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -